

Page 1/9

Safety Data Sheet acc. to OSHA HCS

Printing date 10/09/2020

Revision date 10/09/2020

1 Identification

· Product identifier

- · Trade name: APP (C99 Fragment) Monoclonal Antibody (Clone 8G4)
- · Synonym

APPI; ABPP; Alzheimer's Disease Amyloid Protein; Amyloid Precursor Protein; Amyloid-β A4 Protein; Cerebral Vascular Amyloid Peptide' CVAP; PreA4; Protease Nexin-II

- · Article number: 28636
- Application of the substance / the mixture For research use only, not for human or veterinary use.
- Details of the supplier of the safety data sheet
 Manufacturer/Supplier: Cayman Chemical Co. 1180 E. Ellsworth Rd.

Ann Arbor, MI 48108 USA

· Information department: Product safety department

• Emergency telephone number: During normal opening times: +1 (734) 971-3335 US/CANADA: 800-424-9300 Outside US/CANADA: 703-741-5970

2 Hazard(s) identification

• Classification of the substance or mixture The product is not classified, according to the Globally Harmonized System (GHS).

· Label elements

- · GHS label elements None
- · Hazard pictograms None
- Signal word None
- · Hazard statements None
- · Classification system:
- NFPA ratings (scale 0 4)



· HMIS-ratings (scale 0 - 4)

HEALTHIHealth = 0FIRE1Fire = 1REACTIVITY0Reactivity = 0

- · Other hazards
- Results of PBT and vPvB assessment
- · **PBT:** Not applicable.
- · vPvB: Not applicable.

Printing date 10/09/2020

Revision date 10/09/2020

Trade name: APP (C99 Fragment) Monoclonal Antibody (Clone 8G4)

(Contd. from page 1)

Composition/information on ingredients Chemical characterization: Mixtures Description: Mixture of the substances listed below with nonhazardous additions.		
· Dangerous compone	ents:	
CAS: 56-81-5 RTECS: MA8050000	Glycerol	50.0%
CAS: 7647-14-5 RTECS: VZ4725000	Sodium chloride	1.0%
· Other ingredients		
CAS: 7732-18-5 RTECS: ZC0110000	Water	48.0%
CAS: 7558-79-4 RTECS: WC4500000	Sodium phosphate, Dibasic	0.44%
CAS: 7778-77-0 RTECS: TC6615500	Potassium phosphate, Monobasic	0.44%
	APP (C99 Fragment) Monoclonal Antibody (Clone 8G4)	0.1%
CAS: 26628-22-8 RTECS: VY8050000	Sodium azide	0.02%

4 First-aid measures

· Description of first aid measures

- General information: No special measures required.
- After inhalation: Supply fresh air; consult doctor in case of complaints.
- After skin contact: Generally the product does not irritate the skin.
- After eye contact: Rinse opened eye for several minutes under running water.
- After swallowing: If symptoms persist consult doctor.
- Information for doctor:
- **Most important symptoms and effects, both acute and delayed** May cause anemia, cough, CNS depression, drowsiness, headache, heart damage, lassitude (weakness, exhaustion), liver damage, narcosis, reproductive effects, teratogenic effects. No further relevant information available.
- **Indication of any immediate medical attention and special treatment needed** No further relevant information available.

5 Fire-fighting measures

- Extinguishing media
- Suitable extinguishing agents:

Use fire fighting measures that suit the environment.

A solid water stream may be inefficient.

• Special hazards arising from the substance or mixture No further relevant information available.

- Advice for firefighters
- Protective equipment: No special measures required.

(Contd. on page 3)

US

Printing date 10/09/2020

Revision date 10/09/2020

Trade name: APP (C99 Fragment) Monoclonal Antibody (Clone 8G4)

(Contd. from page 2)

6 Accidenta	al release measures	
Environmer Dilute with p Do not allow Methods an Absorb with Reference t See Section See Section See Section	ecautions, protective equipment and emergency procedures Not requir ntal precautions: lenty of water. to enter sewers/ surface or ground water. d material for containment and cleaning up: liquid-binding material (sand, diatomite, acid binders, universal binders, saw o other sections 7 for information on safe handling. 8 for information on personal protection equipment. 13 for disposal information. Action Criteria for Chemicals	
· PAC-1:		
56-81-5	Glycerol	45 mg/m ³
7778-77-0	Potassium phosphate, Monobasic	9.6 mg/m ³
26628-22-8	Sodium azide	0.026 mg/m³
PAC-2:		
56-81-5	Glycerol	180 mg/m ³
7778-77-0	Potassium phosphate, Monobasic	110 mg/m ³
26628-22-8	Sodium azide	0.29 mg/m ³
· PAC-3:		
56-81-5	Glycerol	1,100 mg/m ³
7778-77-0	Potassium phosphate, Monobasic	630 mg/m³
26628-22-8	Sodium azide	5.3 mg/m³

7 Handling and storage

· Handling:

- · Precautions for safe handling No special measures required.
- · Information about protection against explosions and fires: No special measures required.
- Conditions for safe storage, including any incompatibilities Keep container tightly closed.

Store in accordance with information listed on the product insert.

- · Storage:
- · Requirements to be met by storerooms and receptacles: No special requirements.
- · Information about storage in one common storage facility: Not required.
- · Further information about storage conditions: None.
- Specific end use(s) No further relevant information available.

8 Exposure controls/personal protection

• Additional information about design of technical systems: No further data; see item 7.

(Contd. on page 4)

LIS

Printing date 10/09/2020

Revision date 10/09/2020

Trade name: APP (C99 Fragment) Monoclonal Antibody (Clone 8G4)

(Contd. from page 3)

US

Com	
	1-5 Glycerol
PEL	Long-term value: 15* 5** mg/m ³ mist; *total dust **respirable fraction
τιν	TLV withdrawn-insufficient data human occup. exp.
	-14-5 Sodium chloride
PEL	Long-term value: 10 ppm
TLV	Long-term value: 10 mg/m³, 10 ppm
Add	tional information: The lists that were valid during the creation were used as basis.
Gen	onal protective equipment: eral protective and hygienic measures:
Brea	usual precautionary measures for handling chemicals should be followed. thing equipment: Not required. ection of hands:
Brea Prot The Due	
Brea Prot The Due prep Sele degr	thing equipment: Not required. ection of hands: glove material has to be impermeable and resistant to the product/ the substance/ the preparati to missing tests no recommendation to the glove material can be given for the product/ aration/ the chemical mixture. ction of the glove material on consideration of the penetration times, rates of diffusion and adation
Brea Prot The Due prep Sele degr Mate The qual subs be cl	thing equipment: Not required. ection of hands: glove material has to be impermeable and resistant to the product/ the substance/ the preparati to missing tests no recommendation to the glove material can be given for the product/ aration/ the chemical mixture. ction of the glove material on consideration of the penetration times, rates of diffusion and adation erial of gloves selection of the suitable gloves does not only depend on the material, but also on further markity and varies from manufacturer to manufacturer. As the product is a preparation of sev tances, the resistance of the glove material can not be calculated in advance and has therefore the calculated prior to the application.
Brea Prot The Due prep Sele degr Mate The qual subs be cl Pene The	thing equipment: Not required. ection of hands: glove material has to be impermeable and resistant to the product/ the substance/ the preparati to missing tests no recommendation to the glove material can be given for the product/ aration/ the chemical mixture. ction of the glove material on consideration of the penetration times, rates of diffusion and adation erial of gloves selection of the suitable gloves does not only depend on the material, but also on further markity and varies from manufacturer to manufacturer. As the product is a preparation of severation the suitable glove material can not be calculated in advance and has therefore

Information on basic physical and General Information		
Appearance:		
Form:	According to product specificationCharacteristicage BufferPBS, pH 7.2, with 50% glycerol and 0.02% sodium azide	
Color:		
Odor:		
Storage Buffer		
Odor threshold:		
Formulation	100 µg of protein G-purified monoclonal antibody	
pH-value at 20 °C (68 °F):	7.2	
Change in condition		
Melting point/Melting range:	Undetermined.	
Boiling point/Boiling range:	100 °C (212 °F)	
Flash point:	199 °C (390.2 °F)	

Printing date 10/09/2020

Revision date 10/09/2020

Trade name: APP (C99 Fragment) Monoclonal Antibody (Clone 8G4)

	(Contd. from page 4)
 Flammability (solid, gaseous): 	Not applicable.
· Decomposition temperature:	Not determined.
· Auto igniting:	Product is not selfigniting.
· Danger of explosion:	Product does not present an explosion hazard.
 Explosion limits: Lower: Upper: 	Not determined. Not determined.
· Vapor pressure at 20 °C (68 °F):	23 hPa (17.3 mm Hg)
· Density at 20 °C (68 °F):	0.99795–1.00205 g/cm³ (8.32789–8.36211 lbs/gal)
 Bulk density: Relative density Vapor density Evaporation rate 	998–1,002 kg/m ³ Not determined. Not determined. Not determined.
Solubility in / Miscibility with Water:	Fully miscible.
· Partition coefficient (n-octanol/wat	er): Not determined.
 Viscosity: Dynamic: Kinematic: 	Not determined. Not determined.
 Solvent content: Organic solvents: Water: VOC content: 	50.0 % 48.0 % 0.00 % 0.0 g/l / 0.00 lb/gal
Solids content: • Other information	1.1 % No further relevant information available.

10 Stability and reactivity

· Reactivity No further relevant information available.

· Chemical stability

- Thermal decomposition / conditions to be avoided: No decomposition if used according to specifications.
- Possibility of hazardous reactions No dangerous reactions known.
- Conditions to avoid No further relevant information available.
- · Incompatible materials: No further relevant information available.
- · Hazardous decomposition products: No dangerous decomposition products known.

(Contd. on page 6)

US

Printing date 10/09/2020

Revision date 10/09/2020

Trade name: APP (C99 Fragment) Monoclonal Antibody (Clone 8G4)

(Contd. from page 5)

Acute toxicity:			
LD/LC50 values that are relevant for classification: ATE (Acute Toxicity Estimate)			
Oral	LD50	300,000 mg/kg (rat)	
56-81-5 Glycero		10 000 mg/kg (rot)	
Oral	LD50	12,600 mg/kg (rat)	
	Irritation	500 mg/24h (rabbit)	
Irritation of eyes		500 mg/24h (rabbit)	
	Intraperitoneal LD50		
7047 44 5 0 a dia	Subcutaneous LD50	100 mg/kg (rat)	
7647-14-5 Sodiu	im chloride	1000 mg/kg (mgg)	
Oral	-	1,000 mg/kg (man)	
	TDLO	650 ml/kg (man)	
	LD50	4,000 mg/kg (mouse)	
		3,000 mg/kg (rat)	
Inhalative	LD50 LC50	4 g/kg (mouse)	
IIIIalalive	TCLO	320 mg/m ³ (mouse)	
	LCLO	0.63 mg/m³ (hmn) 29,300 mg/m³/7h (mouse)	
Irritation of alkin	Irritation		
		500 mg/24h (rabbit) 100 mg/24h (rabbit)	
Irritation of eyes		2,602 mg/kg (mouse)	
	Subcutaneous LD50		
	Intravenous LD50	59.5 mg/kg (rat)	
	Data	15 mg/3D (hmn)	
	Subcutaneous LD50	- · · ·	
Primary irritant		3 g/kg (mouse)	
on the skin: No			
on the eye: No i			
	lo sensitizing effects k		
	ological information	cation according to internally approved calculation methods	
preparations:	-		
		o specifications, the product does not have any harmful effe formation provided to us.	
Carcinogenic ca	ategories		
IARC (Internatio	onal Agency for Rese	earch on Cancer)	
None of the ingre	edients is listed.		
	oxicology Program)		
None of the ingre	edients is listed.		

Printing date 10/09/2020

Revision date 10/09/2020

Trade name: APP (C99 Fragment) Monoclonal Antibody (Clone 8G4)

(Contd. from page 6)

· OSHA-Ca (Occupational Safety & Health Administration)

None of the ingredients is listed.

12 Ecological information

- · Toxicity
- Aquatic toxicity: No further relevant information available.
- Persistence and degradability No further relevant information available.
- · Behavior in environmental systems:
- · Bioaccumulative potential No further relevant information available.
- · Mobility in soil No further relevant information available.
- · Additional ecological information:
- · General notes:

Water hazard class 1 (Self-assessment): slightly hazardous for water

Do not allow undiluted product or large quantities of it to reach ground water, water course or sewage system.

- Results of PBT and vPvB assessment
- **PBT:** Not applicable.
- **vPvB:** Not applicable.
- Other adverse effects No further relevant information available.

13 Disposal considerations

- · Waste treatment methods
- Recommendation: Smaller quantities can be disposed of with household waste.
- · Uncleaned packagings:
- **Recommendation:** Disposal must be made according to official regulations.
- Recommended cleansing agent: Water, if necessary with cleansing agents.

14 Transport information

· UN-Number · DOT, IMDG, IATA	not regulated	
· UN proper shipping name · DOT, IMDG, IATA	not regulated	
Transport hazard class(es)		
DOT, ADN, IMDG, IATA Class	not regulated	
· Packing group · DOT, IMDG, IATA	not regulated	
Environmental hazards:	Not applicable.	
Special precautions for user	Not applicable.	
 Transport in bulk according to Annex MARPOL73/78 and the IBC Code 	II of Not applicable.	
		(Contd. on page

Printing date 10/09/2020

Revision date 10/09/2020

Trade name: APP (C99 Fragment) Monoclonal Antibody (Clone 8G4)

(Contd. from page 7)

• UN "Model Regulation":

not regulated

15 Regulatory information

Sara	h and environmental regulations/legislation specific for	the substance or mixture
	extremely hazardous substances):	
26628-22-8	Sodium azide	
· Section 313	Specific toxic chemical listings):	
26628-22-8	Sodium azide	
TSCA (Toxic	Substances Control Act):	
56-81-5 (Glycerol	ACTIVE
7732-18-5 V	Vater	ACTIVE
7647-14-5 \$	Sodium chloride	ACTIVE
7558-79-4 S	Sodium phosphate, Dibasic	ACTIVE
7778-77-0 F	Potassium phosphate, Monobasic	ACTIVE
26628-22-8	Sodium azide	ACTIVE
· Hazardous A	ir Pollutants	
None of the ir	ngredients is listed.	
· Proposition	65	
[·] Chemicals ki	nown to cause cancer:	
None of the ir	igredients is listed.	
· Chemicals ki	nown to cause reproductive toxicity for females:	
None of the ir	gredients is listed.	
· Chemicals ki	nown to cause reproductive toxicity for males:	
None of the ir	ngredients is listed.	
· Chemicals ki	nown to cause developmental toxicity:	

None of the ingredients is listed.

· Carcinogenic categories

· EPA (Environmental Protection Agency)

None of the ingredients is listed.

• TLV (Threshold Limit Value established by ACGIH)

26628-22-8 Sodium azide

· NIOSH-Ca (National Institute for Occupational Safety and Health)

None of the ingredients is listed.

· Chemical safety assessment: A Chemical Safety Assessment has not been carried out.

16 Other information

This information is based on our present knowledge. However, this shall not constitute a guarantee for any specific product features and shall not establish a legally valid contractual relationship.

· Department issuing SDS: Environment protection department.

· Contact: -

A4

Printing date 10/09/2020

Revision date 10/09/2020

Trade name: APP (C99 Fragment) Monoclonal Antibody (Clone 8G4)

	(Contd. from page 8
Date of preparation / last revision 10/09/2020 / -	(conta: nom page t
Abbreviations and acronyms:	
IMDG: International Maritime Code for Dangerous Goods	
DOT: US Department of Transportation	
IATA: International Air Transport Association	
ACGIH: American Conference of Governmental Industrial Hygienists	
EINECS: European Inventory of Existing Commercial Chemical Substances	
ELINCS: European List of Notified Chemical Substances	
CAS: Chemical Abstracts Service (division of the American Chemical Society)	
NFPA: National Fire Protection Association (USA)	
HMIS: Hazardous Materials Identification System (USA)	
VOC: Volatile Organic Compounds (USA, EU)	
LC50: Lethal concentration, 50 percent	
LD50: Lethal dose, 50 percent	
PBT: Persistent, Bioaccumulative and Toxic	
vPvB: very Persistent and very Bioaccumulative	
NIOSH: National Institute for Occupational Safety	
OSHA: Occupational Safety & Health	
TLV: Threshold Limit Value	
PEL: Permissible Exposure Limit	
REL: Recommended Exposure Limit	
* Data compared to the previous version altered.	
····· F······ F· ···· · F· ····	